An observational study in Lung Nodules, sponsored by Biodesix, Inc.. Active, not recruiting at 5 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-02-07.
Sponsored by Biodesix, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a multicenter retrospective chart review. Sites with at least 100 patients tested with the IC and AAT tests, who have index dates (date of IC and AAT testing) at least one year prior to data collection date will be eligible for participation.
This study is a multicenter retrospective chart review. Sites with at least 100 patients tested with the IC and AAT tests, who have index dates (date of IC and AAT testing) at least one year prior to data collection date will be eligible for participation.
The protocol will require institutional IRB approval and a waiver of patient consent will be obtained. The data to be collected will be de-identified when entered into the study database. The collection of this de-identified data does not pose any risk to the subjects and does not require any further testing of the patient. The chart review will utilize a third-party Clinical Research Associate (CRA) with certified ICH-GCP training for data collection and documentation. Biodesix, Inc. in conjunction with the CRA will develop and maintain the Electronic Data Capture (EDC) system.
Biodesix, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients that have previously been tested with the AAT and IC tests and have at least 1 year of follow up data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Assess Test Performance of AAT test
To assess the performance of the AAT test in a real-world patient population: 1. Sensitivity of the AAT test at 24 months 2. Specificity of the AAT test at 24 months 3. Positivity predictive value of the AAT test at 24 months
Time frame: Up to 24 months
Assess Test Performance of IC test
To assess the performance of the IC test in a real-world population: 1. Sensitivity of the IC test at 24 months 2. Specificity of the IC test at 24 months 3. Negative predictive value of the IC test at 24 months
Time frame: 24 months
Assess serial performance of serial testing with the AAC and IC tests.
Assess the performance of the of serial testing with the AAC and IC tests
Time frame: 24 months
Assess ATT Test Accuracy
To assess the accuracy of the AAT post-test risk of malignancy by comparing with the actual patient outcome. * Compare the AAT test predicted proportion of malignant nodules to the actual proportion of malignant nodules by probability decile. * Compare the IC test predicted proportion of malignant nodules to the actual proportion of malignant nodules by probability decile.
Time frame: Up to 24 months
Determine Health Outcomes
To determine one-year health outcomes of patients stratified by AAT and IC tests result risk categories. * The number and type of invasive diagnostic procedure performed on newly identified nodules stratified by AAT test results. * The number of patients routed to CT surveillance following initial nodule evaluation that result in nodule resolution or up to 24-month radiographic stability stratified by the AAT test. * The number and type of invasive diagnostic procedures performed on newly identified nodules stratified by IC test results. * The number of patients routed to CT surveillance following initial nodule evaluation that result in nodule resolution or up to 24-month radiographic stability stratified by the IC test. * The number of malignant nodules identified following a diagnostic procedure stratified by histology and stage. * The number of specific benign nodules identified following a diagnostic procedure, stratified by pathological findings.
Time frame: Up to 24 months
Assess Test Performance in Sub-Populations
Assess the performance of the AAT and IC tests in patient subpopulations. 1. Sensitivity of the AAT test in patient sub-populations at 24 months 2. Specificity of the AAT test in patient sub-populations at 24 months 3. Positivity predictive value of the AAT in patient sub-populations test at 24 months 4. Sensitivity of the IC test in patient sub-populations at 24 months 5. Specificity of the IC test in patient sub-populations at 24 months 6. Negative predictive value of the IC test in patient sub-populations at 24 months
Time frame: Up to 24 months
Assess Test Performance in Populations Outside of Validation
To assess the performance of the AAT and IC tests in populations outside of their primary validated populations. 1. Sensitivity of the AAT test in patient sub-populations at 24 months 2. Specificity of the AAT test in patient sub-populations at 24 months 3. Positivity predictive value of the AAT in patient sub-populations test at 24 months 4. Sensitivity of the IC test in patient sub-populations at 24 months 5. Specificity of the IC test in patient sub-populations at 24 months 6. Negative predictive value of the IC test in patient sub-populations at 24 months
Time frame: Up to 24 months
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Jul 2026, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biodesix, Inc.